 Connection
Janet Rader to Survival Analysis
This is a "connection" page, showing publications Janet Rader has written about Survival Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.406 |
|
|
|
-
Iden M, Tsaih SW, Huang YW, Liu P, Xiao M, Flister MJ, Rader JS. Multi-omics mapping of human papillomavirus integration sites illuminates novel cervical cancer target genes. Br J Cancer. 2021 11; 125(10):1408-1419.
Score: 0.171
-
Wright JD, Gibb RK, Geevarghese S, Powell MA, Herzog TJ, Mutch DG, Grigsby PW, Gao F, Trinkaus KM, Rader JS. Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer. 2005 Jan 01; 103(1):85-91.
Score: 0.054
-
Kharofa J, Morrow N, Kelly T, Rownd J, Paulson E, Rader J, Uyar D, Bradley W, Erickson B. 3-T MRI-based adaptive brachytherapy for cervix cancer: treatment technique and initial clinical outcomes. Brachytherapy. 2014 Jul-Aug; 13(4):319-25.
Score: 0.026
-
Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS, Grigsby PW. Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res. 2012 Mar 01; 18(5):1464-71.
Score: 0.022
-
Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader JS, Mutch DG, Grigsby PW. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011 Mar 01; 117(5):948-56.
Score: 0.020
-
Hu X, Schwarz JK, Lewis JS, Huettner PC, Rader JS, Deasy JO, Grigsby PW, Wang X. A microRNA expression signature for cervical cancer prognosis. Cancer Res. 2010 Feb 15; 70(4):1441-8.
Score: 0.019
-
Wright JD, Secord AA, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader JS, Mutch DG. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer. 2008 May-Jun; 18(3):400-6.
Score: 0.016
-
Grigsby PW, Mutch DG, Rader J, Herzog TJ, Zoberi I, Siegel BA, Dehdashti F. Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):444-9.
Score: 0.014
-
Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004 Jun 01; 22(11):2167-71.
Score: 0.013
-
Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL. Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. Ann Oncol. 2002 Nov; 13(11):1819-25.
Score: 0.012
-
Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2002 Apr 01; 20(7):1832-7.
Score: 0.011
-
Cohn DE, Swisher EM, Herzog TJ, Rader JS, Mutch DG. Radical hysterectomy for cervical cancer in obese women. Obstet Gynecol. 2000 Nov; 96(5 Pt 1):727-31.
Score: 0.010
-
Basil JB, Goodfellow PJ, Rader JS, Mutch DG, Herzog TJ. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer. 2000 Oct 15; 89(8):1758-64.
Score: 0.010
-
Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 1997 Sep; 66(3):480-6.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|